Trial Profile
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Brimonidine (Primary)
- Indications Erythema
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Galderma
- 10 Feb 2014 New trial record
- 29 Jan 2014 Study results were published in the Journal of Drugs in Dermatology, according to a Galderma Laboratories media release.